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SNP-based mapping arrays reveal high genomic 
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Monoclonal Gammopathies: from early to late stages Introduction
MGUS MM Normal PC SMM
• MM is a malignant and incurable disorder characterized by the 
accumulation of clonal plasma cells in the bone marrow.
•MM evolves from a previous premalignant condition in most patients1,2.
Monoclonal Gammopathies: from early to late stages Introduction
MGUS MM Normal PC SMM
• MM is a malignant and incurable disorder characterized by the 
accumulation of clonal plasma cell in the bone marrow.
1Landgren et al, Leukemia 2009.  2Weiss et al, Expert. Rev. Hematol  2010 






















a) Myeloma Related Organ or Tissue Impairment (end organ damage) related to Plasma cell proliferative process: anemia with 2 g/dL below the
normal level or <10 g/dL, or serum calcium level >10 mg/L (0.25 mmol/L) above normal or >110 mg/dL (2.75 mmol/L), or lytic bone lesions or
osteoporosis with compressive fractures, or renal insuficiency (creatinine >2 mg/dL or 173 mmol/L),[CRAB: Calcium increase, Renal
impairment, Anemia and Bone lesion] or symptomatic hyperviscosity,, amyloidosis or recurrent bacterial infections (>2 episodes in 12 m).
b) For symptomatic multiple myeloma, a minimum level of M-component or BM plasma cell infiltration (although usually it is >10%, is not
required, provided than this two features coexists with the presence of end organ damage
1International Working Group (BJH 2003; 121:749)
Monoclonal gammopathies: IMWG criteria1 Introduction
MGUS and SMM: risk of progression to symptomatic MM
10% per year 
1% per year
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Secondary IGH translocations: CMYC
Hallek (modified), Blood 1998
Multistep transformation model Introduction
This suggests
The chromosomal regions explored are not involved 
in the malignant transformation 
The progression to MM is associated with subtle 
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A comprehensive high-resolution analysis of 
genomic imbalances from the early to late stages 
of monoclonal gammopathies:
DNA: SNP-arrays
1. Copy number abnormalities (CNA)
2. Copy number neutral LOH (CNN-LOH)








• Cytogenetic Lab 





74 patients with monoclonal gammopathies1
1 IMWG 2003
2 >24 months of stable disease
3Kyle  etl al, NEJM 2007; Perez-persona et al, Blood 2007
4Newly diagnosed untreated patients 
5Only high quality DNA was used  (ND-1000 spectrophotometer )
The study was approved by the research ethics committees and written informed consent was obtained (Helsinky declaration).
AutoMACs separation system




Genome-Wide Human SNP-Array 6.0 assay protocol (Affymetrix)
• Processing (Fluidics Station 450, GeneChip Scanner 3000 7G and AGCC)
• Filter (Contrast quality control > 0.4 y MAPD < 0.35)
• Normalization (240 hapmap file)
ANALYSIS (Genotyping Console 4.0 –Affymetrix-, dCHIP y ChAS –Affymetrix-, SPSS 15)
1. > 10 markers per segments
2. > 100 Kb minimun genomic sizes
3. <50% overlap with known CNV





Example of a normal chromosome 
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Example of a monosomy Material and Methods
Chromosome 13




Example of a trisomy in a minor subclone Material and Methods
Chromosome 11




A comprehensive high-resolution analysis of 
genomic imbalances from early to late stages of 
monoclonal gammopathies:
DNA: SNP-arrays
1. Copy number abnormalities (CNA)
2. Copy number neutral LOH (CNN-LOH)
3. Correlation with fragile sites (FRA) 
Results
Copy number abnormalities Results
1CNA= copy number alterations
-
+
• CNA1 were identified in 93% (69/74 patients)
• Two MGUS and three SMM patients with no CNA
Progressive increase in the incidence of CNA1 from 
MGUS to HR-SMM and to MM
Global CNA GAINS LOSSES
Median (range) Median (range) Median (range)
MGUS (N=20) 5 (0-12) 1,5 (0-8) 1,5 (0-9)
HR-SMM (N=20) 7,5 (0-23) 3 (0-12) 3,5 (0-14)
MM (N=34) 12 (1-32) 6,5 (1-20) 4 (0-29)
SMM vs MM p=0,025
MGUS vs MM P= 0,006 MGUS vs MM P= 0,000 MGUS vs MM P= 0,033
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1CNA= copy number alterations
• CNA1 were identified in 93% (69/74 patients)
• Two MGUS and three SMM patients with no CNA
Results
Percentages of aberrations per chromosome 


















































% accumulated of cases 
MGUS SMM MM
GAINS LOSSES 
* MGUS vs. MM
* MGUS vs. MM
* MGUS vs. MM
* MGUS vs. MM
* SMM vs. MM
* MGUS and SMM vs. MM
* MGUS and SMM vs. MM
* GMSI y MMQ vs. MM
* MGUS and SMM vs. MM
MGUS vs. MM *
SMM vs. MM *
MGUS vs. SMM and MM *
MGUS vs. MM *













1q 20% (4/20) 40% (8/20) 59% (20/34) P=0.013 (MGUS vs MM)
3p 10% (2/20) 25% (5/20) 38% (13/34) P=0.05 (MGUS vs MM)
6p 5% (1/20) 15% (3/20) 26% (9/34) P=0.05 (MGUS vs MM)
9p 25% (5/20) 40% (8/20) 59% (20/34) P=0.034 (MGUS vs MM)
11p 10% (2/20) 5% (1/20) 35% (12/34) P=0.019 (MGUS vs MM)
11q 0% (0/20) 10% (2/20) 47% (16/34) P=0.001 (MGUS vs MM)P=0.013 (SMM vs MM)
19p 25% (5/20) 30% (6/20) 65% (22/34) P=0.011 (MGUS vs MM)P=0.029 (SMM vs MM)
19q 25% (5/20) 20% (4/20) 56% (19/34) P=0.05 (MGUS vs MM)P=0.022 (SMM vs MM)








1p 5% (1/20) 25% (5/20) 44% (15/34) P=0.006 (MGUS vs MM)
4q 5% (1/20) 0% (0/20) 21% (7/34) P=0.038 (SMM vs MM)
16q 0% (0/20) 30% (6/20) 21% (7/34) P=0.02 (MGUS vs SMM)P=0.038 (MGUS vs MM)
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1p 5% (1/20) 25% (5/20) 44% (15/34) P=0.006 (MGUS vs MM)
4q 5% (1/20) 0% (0/20) 21% (7/34) P=0.038 (SMM vs MM)
16q 0% (0/20) 30% (6/20) 21% (7/34) P=0.02 (MGUS vs SMM)P=0.038 (MGUS vs MM)
22q 0% (0/20) 15% (3/20) 23% (8/34) P=0.020 (MGUS vs MM)


















































































































































































































































ResultsPercentages of cases carrying specific CNA as 
minor and major subpopulations 








16 17 20 22
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Losses on the left
Gains on the right
MGUS SMM MM
Gained and lost minimal common regions (MCR) Results
Homozygous deletions (HZD)
Patients Band Start (Kb) End (Kb) Size (Kb)  Genes
15_MGUS 1q25.1 173068.5 173063.2 5.3 RABGAP1L
13_MGUS 1q31,1 195077.6 194981.6 96.0 CFHR1, CFHR3
15_MGUS 2p22.3 34590.3 34546.8 43.5
19_MGUS 2p22.3 34590.6 34549.7 40.9
66_MM 3q26.1 163626.5 163612.0 14.5
11_MGUS 6q14.1 79092.9 79020.7 72.3
9_MGUS 8p11.23-p11.22 39507.6 39350.8 156.8 ADAM3A
19_MGUS 8p11.23-11.22 39506.4 39354.1 152.3 ADAM3A
56_MM 11q22.1-q22.2    102013.9 101523.2 490.7
TRPC6, ANGPTL5, KIAA1377, C11orf70, YAP1, BIRC3, BIRC2, 
TMEM123, MMP7, MMP20 
40_SMM 13q32.1 94715.6 93912.0 803.6 DCT, TGDS, GPR180, SOX21, ABCC4
74_MM 19q13.31 48434.2 48239.1 195.0 PSG2, PSG5, PSG4, PSG9
40_SMM 22q11.22 21556.1 21110.4 445.7 ZNF280B, ZNF280A, PRAME, GGTL4
• 12 HZD corresponding to 5 MGUS (25%), 1 SMM (5%) and 3 MM (9%).
• 10 different chromosomal regions involved. 




A comprehensive high-resolution analysis of 
genomic imbalances from the early to late stages 
of monoclonal gammopathies:
DNA: SNP-arrays
1. Copy number abnormalities (CNA)
2. Copy number neutral LOH (CNN-LOH)
3. Correlation with fragile sites (FRA) 
Results
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• 38% of patients (28/74) showed CNN-LOH 
• 58 CNN-LOH (52 partial, 6 complete). Median: 2 (1-5)
• 7 copy number gain LOH*.
1 3 4 5 6 7 8 9 10 11 12
13 14 15 16 17 18 19 20 21 22
1 2 3 4 5 6 7 8 9 10 11 12














Copy number neutral-LOH and Copy number gain-LOH* Results
A comprehensive high-resolution analysis of 
genomic imbalances from the early to late stages 
of monoclonal gammopathies:
DNA: SNP-arrays
1. Copy number abnormalities (CNA)
2. Copy number neutral LOH (CNN-LOH)





• 55% of MCR
• 65% of CNN-LOH and 58% of CNG-LOH
• 40% of HZD
FRA
Correlation with fragile sites (FRA)
• ±110 FRA described*
• Correlation between FRA and cancer 
breakpoints in solid tumors. 
• For example: FRA16D (16q23.3): WWOX.




• 55% of MCR
• 65% of CNN-LOH and 58% of CNG-LOH
• 40% of HZD
FRA
• ±110 FRA described*
• Correlation between FRA and cancer 
breakpoints in solid tumors. 
• For example: FRA16D (16q23.3): WWOX.
Underexpressed in MM cases with 16q LOH or 
t(14;16)
ResultsCorrelation with fragile sites (FRA)
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 The whole genome analysis using SNP-arrays revealed an 
increasing genomic complexity from MGUS to SMM and 
to MM. 
 The transition from MGUS to MM was not associated with 
a particular chromosomal imbalance, but rather with an 
expansion of altered clones that were already present in 
MGUS.
 More than a half of the genetic lesions were located at 
fragile sites.
Summary
 The whole genome analysis using SNP-arrays revealed an 
increasing genomic complexity from MGUS to SMM and 
to MM. 
 The transition from MGUS to MM was not associated with 
a particular chromosomal imbalance, but rather with an 
expansion of altered clones that were already present in 
MGUS.
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